Umbilical cord mesenchymal stem cell therapy - Kangstem Biotech
Alternative Names: FURESTEM; FURESTEM-AD; FURESTEM-AD inj; FURESTEM-CD; FURESTEM-CD Inj; FURESTEM-OA Kit Inj; FURESTEM-RA; hUCB-MSCsLatest Information Update: 04 Sep 2023
At a glance
- Originator Kangstem Holdings
- Developer Daewoong Pharmaceutical; Kangstem Biotech
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Atopic dermatitis
- Phase II Rheumatoid arthritis
- Phase I/II Crohn's disease; Epidermolysis bullosa dystrophica
- No development reported Plaque psoriasis
- Discontinued Amyotrophic lateral sclerosis; Cancer; Diabetes mellitus; Niemann-Pick diseases; Pain; Retinal disorders
Most Recent Events
- 31 Aug 2023 Kang Stem Biostem plans a follow-up observational trial (K0701-E) for Knee Osteoarthritis who participated in K0701 trial (NCT06013306)
- 14 Jul 2023 Kangstem Biotech plans a phase I/II trial for Osteoarthritis (Intra-articular) (NCT05944627)
- 06 Jul 2023 Kang Stem Biotech plans a phase I/II trial K0701 for Knee Osteoarthritis (NCT05944627)